BioCentury | Feb 3, 2017
Company News

Abilita deal

Abilita partnered with an undisclosed pharmaceutical company to use its EMP membrane protein evolution platform to discover and develop proteins that target GPCRs. Abilita will receive an upfront payment and is eligible for milestones. Abilita...
BioCentury | Apr 10, 2014
Cover Story

Pre-EMP-tive strike against GBM

...aggressive form of brain cancer. First, the team showed that EMP2 upregulation directly correlated with EMP2...
...higher levels of EMP2 than the surrounding normal brain tissue. In addition, tumor levels of EMP2...
...with subcutaneous GBM xenografts. The first was Paganini's PG-101 anti-EMP2 mAb. The second was an anti-EMP2...
BioCentury | Apr 10, 2014
Distillery Therapeutics

Indication: Cancer

...brain tumor samples, EMP2 expression was higher than that in healthy brain tissue, and elevated EMP2...
...survival. In two heterotopic xenograft mouse models of GBM, an antibody fragment or IgG targeting EMP2...
...to decreased tumor growth compared with fragment or IgG controls. Next steps include testing the EMP2-targeting...
BioCentury | Sep 22, 2011
Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Modeling HIV infection with transgenic cats Transgenic cats expressing antiviral host factors could be used as models to develop new treatments...
BioCentury | Aug 15, 2005
Product Development

Iressa insights

Ever since Iressa gefitinib received accelerated approval in 2003 for non-small cell lung cancer, AstraZeneca plc has been trying to find a way to identify the 10% of patients who respond to the drug, which...
BioCentury | Aug 15, 2005
Clinical News

Iressa gefitinib: Post-marketing study data

Data from tumor samples of 39 NSCLC patients showed a correlation between low expression levels of the epithelial membrane protein 1 ( EMP1 ) and the probability of high response to treatment (p=0.04). None of the patients...
BioCentury | Aug 15, 2005
Clinical News

Iressa gefitinib: Post-marketing study data

Data from a study in 103 patients with various types of NSCLC resistant to Iressa showed that epithelial membrane protein 1 ( EMP1 ) was expressed in 66% of patients with squamous cell carcinomas and 41% of...
BioCentury | Aug 15, 2005
Clinical News

AstraZeneca preclinical data

Researchers published in the Proceeding of the National Academy of Sciences the identification of epithelial membrane protein 1 ( EMP1 ) as a biomarker of resistance to Iressa gefitinib. In a mouse model of prostate cancer, EMP-1...
BioCentury | Aug 9, 2005
Clinical News

Researchers find marker for Iressa resistance

Researchers published in the Proceedings of the National Academy of Sciences the identification of epithelial membrane protein 1 ( EMP1 ) as a biomarker of resistance to Iressa gefitinib from AstraZeneca (LSE:AZN; AZN). In a mouse model...
BioCentury | Mar 28, 2005
Product Development

Tilting at windmills

Third World Solutions Tilting at windmills The experience of Maxygen Inc. in monetizing the various applications of its directed evolution platform perfectly illustrates the problems companies encounter when they try to commercialize vaccines, even with...
Items per page:
1 - 10 of 12